Nebivolol Pliva (Nebivolol Hydrochloride)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force. It also enhances nitric oxide release from the endothelium, causing blood vessels to relax. The combined actions lower peripheral resistance and arterial pressure while supporting better myocardial oxygen delivery.

The dose of Nebivolol Pliva is individualized by the prescribing clinician based on the patient’s blood pressure, heart‑failure status, age, renal and hepatic function, and other medications. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety data for nebivolol during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Nebivolol Pliva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details and any required import documentation.

Nebivolol is a highly β1‑selective blocker that also promotes nitric‑oxide‑mediated vasodilation, a property not shared by many traditional beta blockers. This dual action can provide better blood‑pressure control with a lower incidence of metabolic side effects, making it a preferred option for patients who need both heart‑rate reduction and vasodilation.

Nebivolol Pliva tablets should be stored at room temperature, below 25 °C, in the original blister or bottle. Keep the container tightly closed, protect from moisture and direct sunlight, and keep out of reach of children.

Nebivolol Pliva is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include marked bradycardia, symptomatic hypotension, and severe allergic reactions such as rash, angioedema, or anaphylaxis. Patients should seek immediate medical attention if they experience fainting, very slow heart rate, sudden severe dizziness, or signs of an allergic response.

Nebivolol is contraindicated in patients with known severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or uncontrolled heart failure. It should also be avoided in individuals with a documented hypersensitivity to nebivolol or any of the tablet’s excipients.